Trends and Gaps in Statin Use for Cardiovascular Disease Prevention in Type 2 Diabetes: A Real-World Study in Shanghai, China
Authors' conclusion
Despite the rise in statin use in T2DM in recent decades, a large proportion of subjects with T2DM did not receive statin therapy.
Study context
- Population
- Patients with T2D, Shanghai Hospital Link Database, 2015–2021; grouped by presence of cardiovascular disease (CVD) (secondary vs primary prevention)
- Participants
- 702,727 patients
- Outcome
- Status and trend of statin use
- Follow-up
- 2015 to 2021
Methodological detailsreal-world, electronic health records, stratified by age and sex
- Real-world
- Electronic health records
- Stratified by age and sex
Main finding
As reported in the abstract
Statin use
Received statin therapy, overall
221 127 patients
31.5%
Received statins for secondary prevention, among patients with CVD
157 622 patients
51.62%
Received statins for primary prevention
15%
Statin use in 2015; trend still rising
28.3%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Statin use by age | 18-39 years 14.0% · 40-59 years 26.8% · 60-74 years 33.35% · 75 and over 36.1% |
| Statin use by sex | Women 29.7% · Men 32.9% |
Statin use by age
- Statin use increased with age
Statin use by sex
- Women less likely to receive statin therapy than men
Original publication
Trends and Gaps in Statin Use for Cardiovascular Disease Prevention in Type 2 Diabetes: A Real-World Study in Shanghai, China. Endocr Pract. Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →